Molecular Diagnostic Firms Curetis And OpGen Announce Merger
The combination of the molecular diagnostic companies is structured as an acquisition of Curetis by OpGen. The merged companies will be a based in the US.
You may also be interested in...
Device financing increased substantially in Q3, thanks to debt raises led by Insulet. Acquisition dollar volume dropped, though, but Siemens' buy of Corindus for $1.1bn was a stand-out. Diagnostics/research tools financing dropped by 28% from Q2, while acquisition value greatly increased due to Exact Sciences' $2.8bn purchase of Genomic Health.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.
The company is sponsoring research on how the blood oxygen sensor feature on its Apple Watch 6 could be applied to specific health problems.